วารสารสมาคมจิตแพทย์แห่งประเทศไทย
Journal of the Psychiatrist
Association of Thailand
ISSN: 0125-6985
บรรณาธิการ มาโนช หล่อตระกูล
Editor: Manote
Lotrakul, M.D.
วารสารสมาคมจิตแพทย์แห่งประเทศไทย
Journal of the Psychiatric association of Thailand
สารบัญ
(content)
Download
in pdf text, table, figure
โอลานซาพีนเปรียบเทียบกับฮาโลเพอริดอลในคนไข้จิตเภทที่ไม่ตอบสนองต่อการรักษา
: การวิเคราะห์ต้นทุน-ประสิทธิผล
Olanzapine
versus Haloperidol in the Treatment of Refractory Schizophrenia:
A Cost-Effectiveness Analysis
รณชัย คงสกนธ์ พ.บ.,น.บ.*
สุวรรณา เรืองกาญจนเศรษฐ์ พ.บ.,ว.ท.ม. **
บทคัดย่อ
วัตถุประสงค์ เพื่อแนะนำแบบจำลองในการวิเคราะห์ต้นทุน-ประสิทธิผลของยา
โดยเปรียบเทียบระหว่างโอลานซาพีน และฮาโลเพอริดอล ซึ่งถือเป็นยาที่ใช้ดั้งเดิมในการรักษาโรคจิตเภทที่ไม่ตอบสนองต่อการรักษา
วิธีการศึกษา ศึกษาจากข้อมูลที่ได้รับจากการทำวิจัยเปรียบเทียบการใช้ยาโอลานซาพีนกับฮาโลเพอริดอล
ในการรักษาคนไข้โรคจิตเภทที่ไม่ตอบสนองต่อการรักษา ผลที่ได้รับจากการรักษาจะถูกนำมาเปรียบเทียบกันทั้งต้นทุนทางตรง
(direct cost) และต้นทุนทางอ้อม (indirect cost) ในแง่มุมของบุคลากรทางการแพทย์ที่โรงพยาบาลรามาธิบดี
ภายในระยะเวลา 1 ปี โ ดยวิเคราะห์แนวทางในการรักษา วิเคราะห์ต้นทุน
วิเคราะห์ความไว เมื่อมีความเปลี่ยนแปลงต้นทุน หรือแนวทางในการรักษาโดยบุคลากรทางการแพทย์
ดังนั้น เมื่อมีการเปลี่ยนแปลงแนวทางในการรักษา ค่าที่ได้จึงสามารถเปลี่ยนแปลงได้
โดยยังคงใช้แบบจำลองเดิม
ผลการศึกษา การรักษาคนไข้
1 คนเพื่อให้ดีขึ้นจากโรคจิตเภทที่ไม่ตอบสนองต่อการรักษา และไม่มีปัญหาข้างเคียง
ต้นทุนในการรักษาด้วยยาโอลานซาพีน คิดเป็นเงินเท่ากับ 668,928.0 บาทต่อปี
ในขณะที่ต้นทุนเมื่อใช้ฮาโลเพอริดอล คิดเป็นเงิน 1,565,337.8 บาทต่อปี
ทำให้โอลานซาพีนสามารถลดค่าใช้จ่ายในได้ถึง 896,409.8 บาทต่อปี จากการวิเคราะห์ความไวเมื่อมีการเปลี่ยนแปลงค่าการตอบสนอง
พบว่าโอลานซาพีนมีข้อได้เปรียบกว่าเมื่อยานี้ให้ผลการตอบสนองต่อการรักษามากกว่าร้อยละ
21.5 และฮาโลเพอริดอลจะมีข้อได้เปรียบเมื่อผลการตอบสนอง ต่อการรักษามากกว่าร้อยละ
27.5 ขึ้นไป
สรุป ผลการวิเคราะห์ทางเศรษฐศาสตร์แสดงให้เห็นว่าจากการที่โอลานซาพีนมี
ประสิทธิผลมากกว่าฮาโลเพอริดอลในคนไข้ที่เป็นโรคจิตเภทที่ไม่ตอบสนองต่อการรักษา
ทำให้สามารถลดต้นทุนในการรักษาพยาบาลในคนไข้กลุ่มนี้ได้
วารสารสมาคมจิตแพทย์แห่งประเทศไทย
2543; 45(1): 71-85.
คำสำคัญ ต้นทุน-ประสิทธิผล
โรคจิตเภทที่ไม่ตอบสนองต่อการรักษา โอลานซาพีน ฮาโลเพอริดอล การวิเคราะห์ความไว
* ภาควิชาจิตเวชศาสตร์
คณะแพทยศาสตร์โรงพยาบาลรามาธิบดี ถนนพระราม 6 กรุงเทพ 10400
** ภาควิชากุมารเวชศาสตร์
คณะแพทยศาสตร์โรงพยาบาลรามาธิบดี ถนนพระราม 6 กรุงเทพ 10400
Ronnachai Kongsakon,
M.D.,LL.B.*
Suwanna Roungkarnjanaset,
M.D., M.Sc.**
Abstract
Objective This study
intends to introduce a model of cost-effective analysis by comparing
olanzapine with haloperidol, which is the conventional treatment
in refractory schizophrenia.
Method Data from clinical
trials were used to compare olanzapine with haloperidol in patients
with refractory schizophrenia. Outcomes were compared among direct
and indirect cost with the view point of health care provider at
Ramathibodi Hospital and society in one year of treatment by path
analysis and cost analysis, sensitivity analysis was shown for clinical
decision when there is some cost or path probability have been changed
so the decision will be changed at some threshold to another alternative.
Results The total cost
of olanzapine treatment to get one healthy of refractory schizophrenia
is 668,928.0 Baht per year. On the other hand the total cost for
haloperidol is 1,565,337.8 Baht per year. Olanzapine provides net
benefit to one by 896,409.8 Baht per year. In the sensitivity analysis
showed that olanzapine will always provide this advantage as long
as the response rate of olanzapine is more than 21.5%. Haloperidol
will provide the same cost effective to the patient if its response
rate is better than 27.5%.
Conclusions
The result of this economic evaluation suggests that the total one
year cost of treatment by olanzapine appears to be more effective
than haloperidol in the treatment of TRS. This is the impact of
the cost reduction of medical care for TRS patients during one year
of treatment.
J
Psychiatr Assoc Thailand 2000; 45(1): 71-85.
Key words : cost effectiveness,
refractory schizophrenia, olanzapine, haloperidol, sensitivity analysis
*Department of Psychiatry, Ramathibodi
Hospital, Mahidol University, Rama 6 Road, Bangkok 10400.
** Department of Pediatric,
Ramathibodi Hospital, Mahidol University, Rama 6 Road,
Bangkok 10400.
Introduction
Schizophrenia
is a severe chronic mental illness affecting approximately 20 million
people worldwide with lifetime prevalence rate 1 %1.
It places a major economic burden on society, in terms of both direct
and indirect cost. The total cost of schizophrenia2 in
1990 in the USA were estimated to be $US32.5 billion, with 53% of
this amount comprising direct medical cost , 37% lost productivity
due to morbidity and premature mortality, and 10% were other cost
such as those attached to family caregivers' time. The amount of
direct medical cost was an average of $US4100 per patient per annum.
Conventional
neuroleptic therapy reduces acute psychosis and recurrence rates.
However, approximately 30% of patients do not respond. Neither did
it exert therapeutic effects against all domains of schizophrenic
pathology, e.g. negative or deficit features3. Equally
important, conventional antipsychotics carry side-effects such as
extrapyramidal symptoms (EPS), tardive dyskinesia (TD), neuroleptic
malignant syndrome (NMS) which compromise patient compliance. Furthermore,
in the NIMH study the relapse/recurrence rate in the neuroleptic
responder group was as high as 78% during 2-12 years of follow up
period4. The care of these patients is further complicated
by the issue of treatment-refractory schizophrenia (TRS).
Clozapine therapy
is the best established treatment for TRS, with a response rate
of about 30-50 %5. Unfortunately, those who benefit often
manifest marked psychopathology, and many TRS patients are unable
to take clozapine for a variety reasons6 especially due
to increase risk of agranulocytosis.
The present
studys aim is to search for other antipsychotic agents with more
benefit. Alternative approaches, implicating other neurotransmitter
systems, have led to the development of novel antipsychotic candidates7.
A prototype is olanzapine, a thienobenzodiazepine. Biochemical studies
have demonstrated that olanzapine has a broad pharmacological profile
with high affinity for serotonin2A/2C, dopamine D1,
D2, muscarinic, alpha1 adrenoreceptors,
and histamine H1 receptors8. Recently, Seeman9
reported that olanzapine, like clozapine, has high affinity for
the dopamine D4 receptor and that an action at this receptor
may contribute to the pharmacological profile of the compound.
Olanzapine
has been currently introduced in Thailand but the cost of the drug
was very high compare to conventional antipsychotics. So its efficacy
and low side effect had to be weighed with its cost, particularly
in the country like Thailand where resources of health care is highly
limited. We therefore carried out this study to compare olanzapine
with the conventional antipsychotic (haloperidol) in TRS by cost
effectiveness analysis. Schizophrenia10 is a chronic
disease, it is a life long treatment for most patients especially
those with TRS. One year period of treatment was used for our economics
analysis because it will cover the response period of the drugs
about 4-8 weeks and the relapse or the complication such as suicide
which occur usually within one year.
The results
of this pharmacoeconomic studies will help clinicians and health
care policy makers to determine which treatment will provide the
most benefit to TRS in term of patients functioning and well-being
at the most acceptable medical cost.
The objectives
of the study were to determine the cost-effectiveness (in Baht,
1998) of olanzapine (OLZ) in the treatment of patients with refractory
schizophrenia compared to haloperidol (HAL) in the view point of
health care provider and society, and to perform the sensitivity
analysis of the main variables that affected the analysis.
Study design
This is an
economic evaluation study using a clinical decision analysis model.
Parameter estimations were based on the information through literature
reviews on clinical trial data, published medical literature and,
when need, clinical judgment in the treatment of refractory schizophrenia
from the perspectives of health care provider and the society.
Operational definition
Refractory schizophrenia:
The criteria used in this study were the original clozapine trials
and were adapted from Kane et al11. The criteria
were:
- patients with schizophrenia
had to have failed in the current episode at least 2 distinct
periods of neuroleptic treatment for at least 2 different
classes,
- the duration of each
neuroleptic treatment at least 6 weeks without symptom relief,
- the dosage of previously
failed neuroleptics must have been more than 750 mg/day
chlorpromazine equivalence,
- there were no period
of substantial relief of symptom as evidence from Brief
Psychiatric Rating Scale (BPRS) >35, and
- the duration of illness
must be more than 2 years.
Critical review
A single, global,
Phase III protocol was conducted in 17 countries involving 178 investigative
sites12. Nineteen hundred and ninety-six patients were
randomized to either OLZ (5 to 20 mg) or HAL (5 to 20 mg). More
patients completed six weeks of acute pharmacotherapy with olanzapine
(66%) than with haloperidol (47%) statistically significant due
to the compliance and the side effect from the drugs. While comparable
reduction in BPRS-positive symptoms (baseline to endpoint) was observed
for OLZ and HAL, the former was statistically significantly superior
on the following efficacy parameters: BPRS total, BPRS negative
symptoms, PANSS (Positive and Negative Symptom Scale) negative,
and CGI (Clinical global impression) severity. Baseline to endpoint
improvement in depression also favored OLZ. Furthermore, OLZ was
associated with a statistically significant lower incidence of EPS.
Significantly greater baseline to endpoint reduction in Simpson-Angus
Rating Scale score was also observed.
Davies and
Drummond13 estimated the relative cost-effectiveness
of clozapine and standard antipsychotic agents in the management
of TRS within the National Health Service. A decision analysis model
was designed on the basis of the study by Revicki et al14
and supplemented by additional data sources. The authors concluded
that clozapine would be no more expensive, and possibly less expensive,
than standard antipsychotic therapy in TRS within a realistic range
of assumptions employed in the model.
Almond et al15
valued the parameters and outcome scores derived mainly from
an international clinical trial with the result a comparison of
the 2 drugs is approximately cost equal.
Sacrist and
Gome16 had reviewed the rate of response to OLZ with
TRS 36%-48%. It was suggested that OLZ may be effective in a significant
number of neuroleptic-resistant schizophrenic patients and the efficacy
obtained did not necessarily imply an increase in the cost of the
treatment.
From Marders
report17 the rate of response of HAL for TRS was only
12% .
The side effects
of these two drugs were reviewed thoroughly in the study of Casey18
and were used in this current study both parameters and the
side effect probability.
From the study of Hamilton
et al19 there were 14 fewer hospital days per year of
treatment exposure in olanzapine-treated patients compared with
haloperidol-treated patients.
Over a 5-year period, patients
on OLZ had an additional 6.8 months in a disability-free health
state based on BPRS and more than 2 additional months in a disability-free
health state based on quality-adjusted life years, and they experienced
13% fewer relapses compared with patients on HAL20.
Suicide is the most common
form of death among schizophrenic patients and occur in 10%-15%21.
OLZ has been proved to reduce the suicidal rate among the response
more than HAL.
Economic evaluation
Description of the alternatives
Alternative 1 ; Olanzapine
(OLZ) for TRS for one year review all the direct and indirect
cost with the health care
provider and society perspective.
Alternative 2 ; Haloperidol
(HAL) for TRS for one year which is the conventional treatment
with the same analysis as alternative
1.
Outcome
measurement
1. The psychiatric rating scale
for the efficacy was BPRS. For the economic evaluation we will summarize
in term of :
Response to treatment : reduce
in mean score of BPRS ? 35%.
Nonresponse : reduce in mean
score <35%.
2. The psychiatric rating scale
for the side effects measurement was the Simpson-Angus Rating Scale22
(Simpson Angus) for extrapyramidal symptoms.
3. Others :
Laboratory findings such
as CBC (complete blood count), UA (Urinalysis), EKG(Electrocardiogram),
and LFT (liver function test).
Cost Analysis
Direct cost
Cost will be determined
for the fiscal year 1998 and expressed in Thai Baht for each
intervention encounter in each alternative.
Direct medical cost
Cost
determinations
|
Method
of measurement
|
1.
Antipsychotics:
ท Olanzapine
ท Haloperidol
|
ท Cost charge from
the department of pharmacy unit calculated by the dose using
in one year.
Mean dose of OLZ = 17
mg/day
Mean dose of HAL = 25
mg/day
|
2.
Hotel cost |
ท Cost from
the department of finance, Ramathibodi Hospital for the
psychiatric inpatient ward.
|
3.
Labor cost
(health personnel )
|
ท Include psychiatrist,
nurse and paramedics salary per unit cost of patients which
include inpatient treatment and out-patient follow up, also
emergency treatment at emergency unit.
|
4.
Laboratory cost |
ท CBC, UA, EKG, LFT
ท Psychological testing
|
5.
Cost for the treatment of side effects:
ท EPS
ท Tardive dyskinesia
ท Neuroleptic malignant
syndrome
ท Weight gain
ท Hypersomnia
|
ท Cost include the
management per one event. We estimate to be cost for each
alternative by using probability of each side effect.
|
6.
Cost for the complications of the disease: |
|
ท Suicide
attempts treatment
|
ท The treatment need
intensive care and may be the treatment of the complication
from suicide. The cost will be about two fold of normal
admission
|
ท Suicide
with death
|
ท This study would
not calculate the cost because the expected life year was
difficult to be converted into utility due to the condition
of this disease.
|
7.
Non response
ท Usually non-respondents
need electroconvulsive therapy (ECT).
|
ท The analysis will
be based on one admission to have one course of ECT (12
times) which will perform 3 times per week. So the duration
of admission is approximate 28 days.
|
Direct non medical cost
Cost
determinations
|
Method
of measurement
|
ท
Transportation |
ท On the cost
from patients view
|
2. Indirect cost
Cost
determinations
|
Method
of measurement
|
1.
Work loss |
2.
Care-giver loss time and money |
Intangible cost
Cost
determinations
|
Method
of measurement
|
1. Social stigmata
|
2. Reaction to chronic
illness
|
Analysis
Medical Cost The total
direct and indirect medical cost and were analyzed separately in
each alternative by using direct medical cost from Table 1 : olanzapine,
haloperidol group (Table 2 and 3).
Direct nonmedical cost
There were 12 visits per year. The transportation cost of each
visit was 150 Baht. The total cost for one year analysis is 1,800
Baht.
Indirect cost
Work loss: Patients on OLZ
had an additional 6.8 month in a disability-free health state than
HAL/5 years follow up20. So in one year = 1.36 month.
If one day minimal income =162 Baht then HAL treatment group will
have work loss=162 x 40.8 = 6609.6 per year more than OLZ.
Care-giver loss: Since whenever
the patients were disabled, there must be at least one who took
care of them. Therefore, we can assume the same figure as patients
work loss=6609.6 for HAL group more than OLZ.
Cost effectiveness analysis
According to the decision tree
and path probability (Figure 1) the target outcome of this study
is the number of patients who recover from refractory schizophrenia
= healthy without complications and side effects (Outcome 1 and
9).
From Table 2 the cost of OLZ
to get one healthy = 668,928.02
From Table 3 the cost of HAL
to get one healthy = 1,565,337.80
Therefore, net benefit OLZ
over HAL to get one case healthy in one year = 1,565,337.8-668,928.0
= 896,409.8 Baht
Incremental CE ratio
OLZ vs. HAL = total
cost of OLZ total cost of HAL
prob. of healthy (OLZ)
prob. of healthy (HAL)
= 260657.2-78916.58
= 181740.62 = 549,390.63
0.389664-0.05886 0.330804
Sensitivity analysis
The cost of effectiveness of
each alternative may subject to change when there is some change
in cost of the drugs or the efficacy of each drug. Therefore we
vary the response rate of OLZ (Figure 2) and HAL (Figure 3) as well
as the cost of HAL (Figure 4) to get the threshold analysis.
Discussion
The treatment of refractory
schizophrenia (TRS) by using the novel atypical antipsychotic drugs
has been studied in many reports. The efficacy of these drugs has
been proved. However, the cost of these drugs is much more expensive
than the conventional medicine. The cost effectiveness is another
issue needed to be explored especially in developing countries.
The guideline for treatment of TRS should be justified not only
by the effectiveness but also the cost-effectiveness of each particular
drug.
In this study, we compared
the cost effectiveness between olanzapine (OLZ, an atypical antipsychotic
drug) and haloperidol (HAL, a conventional antipsychotic drug) in
the treatment of refractory schizophrenia (TRS) for one-year period.
In attempt to understand the
cost effectiveness of both drugs, the economic analysis was done
by using the decision tree and path probability (Figure 1). It was
shown that in one-year treatment of OLZ providing more benefit over
HAL by 894,409.80 Baht for one patient. In the other word, in order
to get one healthy case the cost of one year treatment by OLZ is
cheaper than HAL by 894,409.80 Baht.
We also used incremental CE
ratio to detect the amount of additional money for the TRS patient
who was currently treated by HAL and want to achieve the equal efficacy
of OLZ. In the incremental CE ratio section, the calculation showed
that we need 549,390.63 Baht to do so.
Even though the price of OLZ
is much higher than HAL (366 Baht/10mg vs. 8.5 Baht/5mg accordingly).
But the cost of complication and side effect treatment causing by
HAL is much more than OLZ. When taking together with the lower response
rate, the total cost of treatment by OLZ is cheaper than HAL.
This assumption was argued
that the response rate of OLZ may be varied from study to study
(38%-48%). We then using the sensitivity analysis to check the minimum
response rate of OLZ which still can provide the advantages of the
drug. As shown in Figure 2, the threshold analysis of OLZ is 21.5%
by using response rate raging from 10% to 40%. This means the cost
effective of OLZ will be over HAL as long as the response rate of
the drug is over 21.5%. On the other way around, if HAL can provide
response rate over 27.5% the cost effectiveness of HAL will be equal
to OLZ (Figure 3).
Both figures answer the argument
of various response rates of both drugs. If the cost of medical
care was fixed these analyses have shown that the final justification
should base on the final threshold of the drugs.
Since the price of HAL is varied
in a wide range. The other argument is if the price of HAL becomes
cheaper the cost effective of HAL may be changed from this conclusion.
In order to find the minimal price of HAL that can compare to OLZ,
We varied the cost of HAL from 1 Baht to 9 Baht per 5mg of HAL tablet
(Figure 4). The cost of treatment consequently varied from 1,330,469
to 1,580,996 Baht per patient per year. When compare to OLZ which
the cost of one patient treatment is 668,928 Baht per year, one
can see that the benefit of OLZ was over HAL at any price within
the range.
The result of this study favored
OLZ when compare to HAL during one year treatment of TRS patient.
However, we realized that the result of economic evaluation will
depend on the period of time, cost estimation of drugs and medical
cares, the response rate of the medications and the adverse event
rate. One who would like to apply this information need to check
all estimation and wisely adapt to each particular circumstance.
Conclusion
The result of this economic
evaluation suggests that the total one year cost of treatment by
OLZ appears to be more effective than HAL in the treatment of TRS.
This is the impact of the cost reduction of medical care for TRS
patients during one year of treatment.
References
- Sartorius N, Giroloano
G. Preface. Schizophr Bull 1991;17:371-3.
- Morris S, Hogan T, McGuire
A. The cost-effectiveness of clozapine. A survey of the literature.
Clin Drug Invest 1997; 15: 137-52.
- Lieberman JA. Understanding
the mechanism of action of atypical antipsychotics. Br J Psychiatry
1993;163:7-18.
- Breier A. NIMH longitudinal
study of chronic schizophrenia: Prognosis and predictors of
outcome. Arch Gen Psychiatry 1991;48:239-46.
- Lindenmayer J, Vital-Herne
M, Bark N, et al. Heterogeneity of serotonergic response in
treatment-refractory schizophrenia patients. Biol Psychiatry
1997;42:6-12 .
- Hong C, Chen J, Chiu H,
et al. A double-blind comparative study of clozapine versus
chlorpromazine on Chinese patients with treatment-refractory
schizophrenia. Int Clin Psychopharmacol 1997; 12: 123-30.
- Meltzer HY. The mechanism
of action of novel antipsychotic drugs. Schizophr Bull 1991;
17: 263-97.
- Bymaster FP, Calligaro
DO, Falcone JF, et al. Radiorecceptor binding profile of the
atypical antipsychotic Olanzapine. Neuropsychopharmacology 1996;
14: 87-96.
- Seeman P, Van Tol HM.
Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 1993;
6: 602-8.
- American Psychiatric Association.
Diagnostic and Statistical Manual of Mental Disorder. 4th
ed. Washington, DC.: American Psychiatric Association, 1994:
285-6.
- Kane JM. Treatment-resistance
schizophrenia patients. J Clin Psychiatry 1996; 57: 35-40.
- Tollefson GD, Charles
M, Tran PV, et al. Olanzapine versus haloperidol in treatment
of shizophrenia and schizoaffective and schizophreniform disorder
: Results of an international collaborative trial. Am J Psychiatry
1997; 154: 457-65.
- Davies LM, Drummond MF.
Assessment of costs and benefits of drug therapy for treatment-resistant
schizophrenia in the United Kingdom. Br J Psychiatry 1993;162:38-42.
- Revicki DA, Luce BR, Weschler
JM, et al. Cost effectiveness of clozapine for treatment-resistant
schizophrenic patients. Hosp Community Psychiatry 1990; 41:
850-4.
- Almond S, O'Donnell. Cost
analysis of the treatment of schizophrenia in the UK: A comparison
of olanzapine and haloperidol. Pharmacol Economics 1998; 13:
575-88.
- Sacristan JA, Gomez JC,
Martin J, et al. Pharmacoeconomic assessment of olanzapine in
the treatment of refractory schizophrenia based on a pilot clinical
study. Clin Drug Invest 1998; 15: 29-35.
- Marder SR. Management
of treatment-resistant patients with schizophrenia. J Clin Psychiatry
1996; 57: 26-30.
- Casey DE. Side effect
profiles of new antipsychotic agent. J Clin Psychiatry 1996;
57: 40-5.
- Hamilton SH, Genduso LA.,
Revicki DA. Medical resource use and work and social outcomes
for olanzapine compared with haloperidol in the treatment of
schizophrenia and other psychotic disorders. Ninth Biennial
Winter Workshop on Schizophrenia. Schizophr Res 1998; 29: 148-9.
- Palmer CS, Revicki DA,
Genduso LA, et al. A cost-effectiveness clinical decision analysis
model for schizophrenia. Am J Managed Care 1998; 4: 345-55.
- Kelleher MJ, Hynes F,
Keeley H. Suicide as a complication of schizophrenia. Ir J Psychol
Med 1998; 15: 24-5.
- Simpson GM, Angus JWS.
A rating scale for extrapyramidal side effects. Acta Psychiatr
Scand 1970; 45 (Suppl212): 11-9.
|